Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01772524 · ClinicalTrials.gov registry record · Phase 1
Safety, Efficacy and Pharmacokinetics of ALD403
A Phase 1 study, sponsored by Alder Biopharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 163
- Enrollment target
NCT01772524: Completed Phase 1 study, sponsored by Alder Biopharmaceuticals.
NCT01772524 is a Phase 1 study that has completed, run by Alder Biopharmaceuticals. The registered enrollment target is 163 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (172% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01772524, a Phase 1 study, has completed, sponsored by Alder Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 163 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, pharmacokinetics and efficacy of a single dose of ALD403 in the prevention of migraine headache in frequent episodic migraineurs for 24 weeks.
Primary Outcome
* Physical Examination * Vital signs * 12-lead ECG (electrocardiogram) * Clinical laboratory tests (hematology, chemistry) * Number of participants with Adverse Events
Interventions
- DRUG Placebo
- BIOLOGICAL ALD403
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163 participants |
| Start Date | 2013-01 |
| Est. Completion | 2014-02 |
| Phase | Phase 1 |
What the finished NCT01772524 record still lists
NCT01772524 is an interventional study that assigns participants to a tested intervention. The registered 163 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (172% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01772524 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01772524 about?
NCT01772524 is a clinical study titled "Safety, Efficacy and Pharmacokinetics of ALD403". The purpose of this study is to assess the safety, pharmacokinetics and efficacy of a single dose of ALD403 in the prevention of migraine headache in frequent episodic migraineurs for 24 weeks.
What is the current status of trial NCT01772524?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 163 participants. The study started on 2013-01. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01772524?
The interventions under investigation include: Placebo (DRUG), ALD403 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01772524?
This trial is sponsored by Alder Biopharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01772524's enrollment target sits among peer trials
163 336th of 2000 higher than 1,665 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03180268 · 163 participants · Phase 3
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
- NCT04862221 · 163 participants · Phase 2
TReatment for ImmUne Mediated PathopHysiology
- NCT05702229 · 163 participants · Phase 2
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- NCT06137118 · 163 participants · Phase 1
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia